论文部分内容阅读
目的:评价曲美他嗪联合通心络胶囊治疗不稳定型心绞痛的疗效。方法:不稳定型心绞痛60例,随机分为两组,均常规口服硝酸酯类、阿司匹林等治疗西药抗心绞痛治疗,治疗组30例在常规治疗的基础上口服(曲美他嗪20m g,3次/d口服;联合通心络胶囊3次/d,4粒/次)对照组30例在常规治疗的基础上口服复方丹参片,3次/d,3片/次。观察两组心绞痛发作次数、持续时间、心电图ST段改变等指标的改善情况。结果:治疗组心绞痛发作次数明显减少,症状改善,总有效率90.0%,与对照组总有效率60%相比较,有统计学差异(P<0.05)。结论:曲美他嗪联合通心络胶囊治疗不稳定型心胶痛疗效确定,值得临床推广。
Objective: To evaluate the efficacy of trimetazidine and Tongxinluo capsule in the treatment of unstable angina pectoris. Methods: Sixty unstable angina pectoris patients were randomly divided into two groups. All patients were treated with oral nitrates and aspirin for anti-angina treatment. 30 patients in the treatment group were treated orally (trimetazidine 20 m g, 3 Times / d oral; combined Tongxinluo capsule 3 times / d, 4 capsules / times) control group of 30 patients on the basis of routine treatment of oral administration of salvia miltiorrhiza tablets, 3 times / d, 3 tablets / time. Two groups were observed angina pectoris episodes, duration, ECG ST segment changes and other indicators of improvement. Results: The number of angina pectoris in treatment group decreased significantly, the symptoms improved, the total effective rate was 90.0%, which was significantly different from the control group (60%) (P <0.05). Conclusion: Trimetazidine combined with Tongxinluo Capsule in the treatment of unstable angina pectoris has definite effect and is worthy of clinical promotion.